Inflammatory disease caused by intestinal pathobionts

Current Opinion in Microbiology

Volumn 35, Issue , 2017, Pages 64-69

  Zechner, Ellen L ^a,b  

^a UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLITIS; COLON CANCER; COLORECTAL CANCER; DYSBIOSIS; GENETIC DISORDER; HUMAN; INFLAMMATORY DISEASE; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PATHOGENICITY; REVIEW; ANIMAL; BACTERIUM; ENTERITIS; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE; MICROBIAL CONSORTIUM; MICROBIOLOGY; MOUSE; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; SYMBIOSIS;

ANIMALS; BACTERIA; CLOSTRIDIUM DIFFICILE; DYSBIOSIS; ENTERITIS; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICE; MICROBIAL CONSORTIA; SYMBIOSIS;

EID: 85012072378     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2017.01.011     Document Type: Review

References (59)

1. 1 Moeller, A.H., Caro-Quintero, A., Mjungu, D., Georgiev, A.V., Lonsdorf, E.V., Muller, M.N., Pusey, A.E., Peeters, M., Hahn, B.H., Ochman, H., Cospeciation of gut microbiota with hominids. Science 353 (2016), 380–382.
2. 2 Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
3. 3 Chung, H., Pamp, S.J., Hill, J.A., Surana, N.K., Edelman, S.M., Troy, E.B., Reading, N.C., Villablanca, E.J., Wang, S., Mora, J.R., et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149 (2012), 1578–1593.
4. 4•• Hajishengallis, G., Lamont, R.J., Dancing with the stars: how choreographed bacterial interactions dictate nososymbiocity and give rise to keystone pathogens, accessory pathogens, and pathobionts. Trends Microbiol 24 (2016), 477–489 In this excellent review Hajishengallis and Lamont develop the concept that commensal and pathogenic properties of organisms are not intrinsic features but need to be perceived in the context of a given microbial community and the host immune status.
5. 5 Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J.T., et al. Human genetics shape the gut microbiome. Cell 159 (2014), 789–799.
6. 6 Wang, J., Linnenbrink, M., Kunzel, S., Fernandes, R., Nadeau, M.J., Rosenstiel, P., Baines, J.F., Dietary history contributes to enterotype-like clustering and functional metagenomic content in the intestinal microbiome of wild mice. Proc Natl Acad Sci U S A 111 (2014), E2703–2710.
7. 7• David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., Ling, A.V., Devlin, A.S., Varma, Y., Fischbach, M.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2014), 559–563 These authors analyze the impact of short-term variation in macronutrients on the human gut microbiome underscoring the view that diet is one of the most potent driving forces shaping gut microbial communities.
8. 8 Forslund, K., Sunagawa, S., Kultima, J.R., Mende, D.R., Arumugam, M., Typas, A., Bork, P., Country-specific antibiotic use practices impact the human gut resistome. Genome Res 23 (2013), 1163–1169.
9. 9 Jernberg, C., Lofmark, S., Edlund, C., Jansson, J.K., Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 1 (2007), 56–66.
10. 10 Sommer, M.O., Dantas, G., Church, G.M., Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325 (2009), 1128–1131.
11. 11 Swaminathan, M., Sharma, S., Poliansky Blash, S., Patel, G., Banach, D.B., Phillips, M., LaBombardi, V., Anderson, K.F., Kitchel, B., Srinivasan, A., et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 34 (2013), 809–817.
12. 12 Becattini, S., Taur, Y., Pamer, E.G., Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med 22 (2016), 458–478.
13. 13 Ubeda, C., Taur, Y., Jenq, R.R., Equinda, M.J., Son, T., Samstein, M., Viale, A., Socci, N.D., van den Brink, M.R., Kamboj, M., et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Investig 120 (2010), 4332–4341.
14. 14 Darkoh, C., DuPont, H.L., Norris, S.J., Kaplan, H.B., Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio, 6, 2015, e02569.
15. 15 Kuehne, S.A., Cartman, S.T., Heap, J.T., Kelly, M.L., Cockayne, A., Minton, N.P., The role of toxin A and toxin B in Clostridium difficile infection. Nature 467 (2010), 711–713.
16. 16 Schneditz, G., Rentner, J., Roier, S., Pletz, J., Herzog, K.A., Bucker, R., Troeger, H., Schild, S., Weber, H., Breinbauer, R., et al. Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis. Proc Natl Acad Sci U S A 111 (2014), 13181–13186.
17. 17 El Feghaly, R.E., Stauber, J.L., Deych, E., Gonzalez, C., Tarr, P.I., Haslam, D.B., Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56 (2013), 1713–1721.
18. 18 Short, F.L., Murdoch, S.L., Ryan, R.P., Polybacterial human disease: the ills of social networking. Trends Microbiol 22 (2016), 508–516.
19. 19 Walters, W.A., Xu, Z., Knight, R., Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett 588 (2014), 4223–4233.
20. 20 Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
21. 21 Butto, L.F., Schaubeck, M., Haller, D., Mechanisms of microbe–host interaction in Crohn's disease: dysbiosis vs. pathobiont selection. Front Immunol, 6, 2015, 555.
22. 22 Ayres, J.S., Trinidad, N.J., Vance, R.E., Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 18 (2012), 799–806.
23. 23 Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J., Peaper, D.R., Bertin, J., Eisenbarth, S.C., Gordon, J.I., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145 (2011), 745–757.
24. 24 Hirota, S.A., Ng, J., Lueng, A., Khajah, M., Parhar, K., Li, Y., Lam, V., Potentier, M.S., Ng, K., Bawa, M., et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17 (2011), 1359–1372.
25. 25 Hu, B., Elinav, E., Huber, S., Strowig, T., Hao, L., Hafemann, A., Jin, C., Wunderlich, C., Wunderlich, T., Eisenbarth, S.C., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci U S A 110 (2013), 9862–9867.
26. 26 Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., Thaiss, C.A., Kau, A.L., Eisenbarth, S.C., Jurczak, M.J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
27. 27 Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104 (2007), 13780–13785.
28. 28 Lupp, C., Robertson, M.L., Wickham, M.E., Sekirov, I., Champion, O.L., Gaynor, E.C., Finlay, B.B., Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe, 2, 2007, 204.
29. 29 Papa, E., Docktor, M., Smillie, C., Weber, S., Preheim, S.P., Gevers, D., Giannoukos, G., Ciulla, D., Tabbaa, D., Ingram, J., et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One, 7, 2012, e39242.
30. 30 Morgan, X.C., Tickle, T.L., Sokol, H., Gevers, D., Devaney, K.L., Ward, D.V., Reyes, J.A., Shah, S.A., LeLeiko, N., Snapper, S.B., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol, 13, 2012, R79.
31. 31 Chassaing, B., Darfeuille-Michaud, A., The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140 (2011), 1720–1728.
32. 32 Winter, S.E., Winter, M.G., Xavier, M.N., Thiennimitr, P., Poon, V., Keestra, A.M., Laughlin, R.C., Gomez, G., Wu, J., Lawhon, S.D., et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339 (2013), 708–711.
33. 33 Winter, S.E., Lopez, C.A., Bäumler, A.J., The dynamics of gut-associated microbial communities during inflammation. EMBO Rep 14 (2013), 319–327.
34. 34 Rigottier-Gois, L., Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J 7 (2013), 1256–1261.
35. 35•• Albenberg, L., Esipova, T.V., Judge, C.P., Bittinger, K., Chen, J., Laughlin, A., Grunberg, S., Baldassano, R.N., Lewis, J.D., Li, H., et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 147 (2014), 1055–1063 e1058 The authors used phosphorescence quenching and a specially designed intraluminal oxygen probe to dynamically quantify gut luminal oxygen levels in mice. Combined with 16S ribosomal RNA gene sequencing to characterize the microbiota the study revealed a radial gradient of microbes linked to the distribution of oxygen and nutrients provided by host tissue.
36. 36 Haberman, Y., Tickle, T.L., Dexheimer, P.J., Kim, M.O., Tang, D., Karns, R., Baldassano, R.N., Noe, J.D., Rosh, J., Markowitz, J., et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Investig 124 (2014), 3617–3633.
37. 37 Gevers, D., Kugathasan, S., Denson, L.A., Vazquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S.J., Yassour, M., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392.
38. 38 Kelly, C.J., Zheng, L., Campbell, E.L., Saeedi, B., Scholz, C.C., Bayless, A.J., Wilson, K.E., Glover, L.E., Kominsky, D.J., Magnuson, A., et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17 (2015), 662–671.
39. 39•• Rivera-Chavez, F., Zhang, L.F., Faber, F., Lopez, C.A., Byndloss, M.X., Olsan, E.E., Xu, G., Velazquez, E.M., Lebrilla, C.B., Winter, S.E., et al. Depletion of butyrate-producing Clostridia from the gut microbiota drives an aerobic luminal expansion of Salmonella. Cell Host Microbe 19 (2016), 443–454 This work describes a remarkable bacterial strategy to control epithelial oxygenation.S. Typhimurium uses its virulence arsenal for selective antagonism of Clostridia. The resulting switch in colonocyte energy metabolism to glucose fermentation raises epithelial oxygenation, which drives aerobic luminal expansion and enhanced pathogen transmission.
40. 40• Chassaing, B., Koren, O., Carvalho, F.A., Ley, R.E., Gewirtz, A.T., AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut 63 (2014), 1069–1080 This study shows that, remarkably, even transient colonization by the pathobiont AIEC during microbiota acquisition in mice lacking the flagellin receptor, TLR5, altered the gut microbiota composition so as to give it an inherently greater ability to activate innate immunity/pro-inflammatory gene expression and resulted in chronic colitis.
41. 41 Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.L., Barnich, N., Bringer, M.A., Swidsinski, A., Beaugerie, L., Colombel, J.F., High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004), 412–421.
42. 42 Sears, C.L., Garrett, W.S., Microbes, microbiota, and colon cancer. Cell Host Microbe 15 (2014), 317–328.
43. 43 Kostic, A.D., Chun, E., Meyerson, M., Garrett, W.S., Microbes and inflammation in colorectal cancer. Cancer Immunol Res 1 (2013), 150–157.
44. 44 Irrazabal, T., Belcheva, A., Girardin, S.E., Martin, A., Philpott, D.J., The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 54 (2014), 309–320.
45. 45 Zackular, J.P., Baxter, N.T., Iverson, K.D., Sadler, W.D., Petrosino, J.F., Chen, G.Y., Schloss, P.D., The gut microbiome modulates colon tumorigenesis. MBio 4 (2013), e00692–00613.
46. 46 Kostic, A.D., Chun, E., Robertson, L., Glickman, J.N., Gallini, C.A., Michaud, M., Clancy, T.E., Chung, D.C., Lochhead, P., Hold, G.L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2013), 207–215.
47. 47 Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., Han, Y.W., Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14 (2013), 195–206.
48. 48• Vizcaino, M.I., Crawford, J.M., The colibactin warhead crosslinks DNA. Nat Chem 7 (2015), 411–417 Structural analyses of colibactin have been hindered due to high instability. These authors employ a combination of NMR spectroscopy and bioinformatics-guided isotopic labeling studies to characterize the colibactin substituted spirobicyclic ‘warhead’ structure. This structure crosslinks duplex DNAin vitro, providing direct experimental evidence for colibactin's DNA-damaging activity.
49. 49 Nougayrede, J.P., Homburg, S., Taieb, F., Boury, M., Brzuszkiewicz, E., Gottschalk, G., Buchrieser, C., Hacker, J., Dobrindt, U., Oswald, E., Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313 (2006), 848–851.
50. 50 Arthur, J.C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
51. 51•• Cougnoux, A., Delmas, J., Gibold, L., Fais, T., Romagnoli, C., Robin, F., Cuevas-Ramos, G., Oswald, E., Darfeuille-Michaud, A., Prati, F., et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65 (2016), 278–285 This study shows that development of small molecule inhibitors of colibactin biosynthesis can control the tumorigenic capacity of pks+ bacteria in a mouse model of CRC.
52. 52 Payros, D., Secher, T., Boury, M., Brehin, C., Menard, S., Salvador-Cartier, C., Cuevas-Ramos, G., Watrin, C., Marcq, I., Nougayrede, J.P., et al. Maternally acquired genotoxic Escherichia coli alters offspring's intestinal homeostasis. Gut Microbes 5 (2014), 313–325.
53. 53 Secher, T., Brehin, C., Oswald, E., Early settlers: which E. coli strains do you not want at birth?. Am J Physiol Gastrointest Liver Physiol 311 (2016), G123–129.
54. 54 Sears, C.L., Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev 22 (2009), 349–369 Table of Contents.
55. 55 Boleij, A., Hechenbleikner, E.M., Goodwin, A.C., Badani, R., Stein, E.M., Lazarev, M.G., Ellis, B., Carroll, K.C., Albesiano, E., Wick, E.C., et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60 (2015), 208–215.
56. 56 Rhee, K.J., Wu, S., Wu, X., Huso, D.L., Karim, B., Franco, A.A., Rabizadeh, S., Golub, J.E., Mathews, L.E., Shin, J., et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 77 (2009), 1708–1718.
57. 57•• Hecht, A.L., Casterline, B.W., Earley, Z.M., Goo, Y.A., Goodlett, D.R., Bubeck Wardenburg, J., Strain competition restricts colonization of an enteric pathogen and prevents colitis. EMBO Rep 17 (2016), 1281–1291 These authors report that colonization of a murine host with symbiotic non-toxigenic Bacteroides fragilis can limit acquisition of pathogenic enterotoxigenic B. fragilis and prevent intestinal inflammatory disease.
58. 58 Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L.G., Gratadoux, J.J., Blugeon, S., Bridonneau, C., Furet, J.P., Corthier, G., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105 (2008), 16731–16736.
59. 59•• Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., Hudault, S., Bridonneau, C., Northen, T., Bowen, B., et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio, 6, 2015 These authors gain insights to mechanisms underlying beneficial effects using a novel gnotobiotic diassociation rodent model in which E. coli primed the gastrointestinal tract allowing a stable establishment of the extreme oxygen-sensitive F. prausnitzii. Metabolic profiling along the GI tract and in the peripheral blood identified signature metabolites linked to anti-inflammatory effects.